Organon And Henlius Advance Perjeta Biosimilar
Partners Publicize Progress On Pertuzumab Product With Positive Phase III Payoff
Organon and Henlius have marked progress on their partnered HLX11 pertuzumab candidate, with the proposed biosimilar to Perjeta meeting the primary endpoint in a Phase III trial.
